Kisqali plus Fulvestrant in women with HR+/HER2- locally advanced or metastatic breast cancer
The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has adopted a positive opinion recommending an expanded indication for Kisqali ( Ribociclib ), the ...
read article